Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis.
<h4>Background</h4>Aldose reductase inhibitors (ARIs) can block the metabolism of the polyol pathway, and have been used to slow or reverse the progression of diabetic cardiovascular autonomic neuropathy (DCAN). The purpose of this study was to review the effectiveness and safety of ARIs...
Guardado en:
Autores principales: | Xin Hu, Shengbing Li, Gangyi Yang, Hua Liu, Guenther Boden, Ling Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/998be66fb3f24a43ab62e77e5274ecbd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity
por: Himangshu Sonowal, et al.
Publicado: (2017) -
Demethylbellidifolin, a potential aldose reductase inhibitor ameliorates diabetic nephropathy by regulating the polyol pathway
por: Haifei Xie, et al.
Publicado: (2022) -
A new approach to control the enigmatic activity of aldose reductase.
por: Antonella Del-Corso, et al.
Publicado: (2013) -
Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat.
por: Kazunori Takahashi, et al.
Publicado: (2012) -
Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications.
por: Shivalika Pathania, et al.
Publicado: (2013)